Comparative Pharmacology
Head-to-head clinical analysis: KINEVAC versus THYROGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KINEVAC versus THYROGEN.
KINEVAC vs THYROGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KINEVAC (sincalide) is a synthetic analog of cholecystokinin (CCK) that stimulates gallbladder contraction and pancreatic secretion by binding to CCK-1 receptors on gallbladder smooth muscle and pancreatic acinar cells, leading to release of bile and pancreatic enzymes.
Recombinant human thyroid-stimulating hormone (TSH) that binds to TSH receptors on thyroid follicular cells, stimulating iodine uptake, thyroglobulin synthesis, and release of thyroid hormones.
KINEVAC (sincalide) is administered as an IV injection or infusion. For gallbladder contraction/cholecystography: 0.02 mcg/kg IV over 30-60 seconds; may repeat once after 15 minutes if inadequate response. For pancreatic function testing: 0.02 mcg/kg IV over 30-60 seconds followed by secretin stimulation.
0.9 mg intramuscular injection every 24 hours for 2 doses, or 1.2 mg orally as a single dose.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 15-30 hours) in patients with normal renal function. Clinically, this supports once-daily dosing.
12-15 hours (terminal elimination half-life in patients with normal renal function; may be prolonged in renal impairment). Clinically, TSH levels peak by 3 hours after IM injection and return to baseline by 24-48 hours.
Biliary/fecal: >90% as unchanged drug; renal: <5% as metabolites.
Primarily renal (thyrotropin is a glycoprotein hormone; intact hormone is minimally excreted unchanged; metabolic degradation products are eliminated renally). After IV administration, approximately 96% of the dose is recovered in urine within 24 hours as low molecular weight degradation products. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Diagnostic Agent, Secretin Analog
Diagnostic Agent